All Journals > The Journal of Infectious Diseases > 1 June 2007 > HLA Class I Genetic Variation and HAART

Article Tools

Search for Related Articles

  • By Author
  • Search In

Announcements

Science Watch logo

JID Article Named "New Hot Paper" by ScienceWatch.com

Dr. Lauri Hicks' 2007 article on pneumococcal disease has been named a "hot new paper" by Thompson Reuters' ScienceWatch.com. Read a Q&A about the article with Dr. Hicks here. 

Press Release

Unique Collaboration Charts the Migrations of a Parasite that Affected History
Researchers Sequence Louse DNA from Mummies and Propose New Model for its Development


In the News

Featured in Grist
"Another symptom of swine flu: instant amnesia" May 11, 2009
Swine Influenza Virus: Zoonotic Potential and Vaccination Strategies for the Control of Avian and Swine Influenzas
Eileen Thacker and Bruce Janke
Read the veterinary literature on swine flu and you get a strong sense of what might be called vaccination treadmill: the hog industry is literally scrambling to generate new vaccines for the rapidly evolving flu strains that sweep through CAFOs. Writing in the Journal of Infectious Diseases [PDF] in 2008, Eileen Thacker and Bruce Janke of Iowa State University paint a stark picture: “A number of genetically diverse viruses are circulating in swine herds throughout the world and are a major cause of concern to the swine industry,” they write. “Influenza virus infections in swine and poultry are potential sources of viruses for the next pandemic among humans.”

Featured in New York Times
"Fear of a Swine Flu Epidemic in 1976 Offers Some Lessons, and Concerns, Today" May 8, 2009
Anti‐Ganglioside Antibody Induction by Swine (A/NJ/1976/H1N1) and Other Influenza Vaccines: Insights into Vaccine‐Associated Guillain‐Barré Syndrome
Irving Nachamkin, Sean V. Shadomy, Anthony P. Moran, Nancy Cox, Collette Fitzgerald, Huong Ung, Adrian T. Corcoran, John K. Iskander, Lawrence B. Schonberger, and Robert T. Chen
Irving Nachamkin, a professor of pathology and laboratory medicine at the University of Pennsylvania, examined some 1976 vaccine that had been saved by a scientist in Texas. In a paper published last year in The Journal of Infectious Diseases, he and colleagues reported that mice given the vaccine made antibodies that reacted with gangliosides, which are components of nerve cells. An antibody attack on gangliosides is part of the disease mechanism of Guillain-Barré.

Featured in AFP
"Swine flu vaccine 'could be ready soon'" May 7, 2009
A Broadly Protective Vaccine against Globally Dispersed Clade 1 and Clade 2 H5N1 Influenza Viruses
Mary A. Hoelscher, Neetu Singh, Sanjay Garg, Lakshmi Jayashankar, Vic Veguilla, Aseem Pandey, Yumi Matsuoka, Jacqueline M. Katz, Ruben Donis, Suresh K. Mittal, and Suryaprakash Sambhara
The vaccine Mittal created for the bird flu worked on three different strains isolated over a seven-year period and was described in papers for the Journal of Infectious Diseases and the journal Clinical Pharmacology and Therapeutics.

Featured in Newsweek
"The Path of a Pandemic" http://www.newsweek.com/id/195692
Swine Influenza Virus: Zoonotic Potential and Vaccination Strategies for the Control of Avian and Swine Influenzas
Eileen Thacker and Bruce Janke
Last year researchers from Iowa State University in Ames warned that pigs located in industrial-scale farms were being subjected to influenza infections from farm poultry, wild birds and their human handlers. Writing in The Journal of Infectious Diseases, Eileen Thacker and Bruce Janke said, "As a result of the constantly changing genetic makeup of individual influenza viruses in pigs, the U.S. swine industry is continually scrambling to respond to the influenza viruses circulating within individual production systems."

1 June 2007

Volume 195, Number 11
The Journal of Infectious Diseases 2007;195:1694–1704
© 2007 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2007/19511-0019$15.00
DOI: 10.1086/516789
MAJOR ARTICLE

Effects of Human Leukocyte Antigen Class I Genetic Parameters on Clinical Outcomes and Survival after Initiation of Highly Active Antiretroviral Therapy

Zabrina L. Brumme,1,2,a,b

Chanson J. Brumme,1,a,b

Celia Chui,1

Theresa Mo,1

Brian Wynhoven,1

Conan K. Woods,1

Bethany M. Henrick,1

Robert S. Hogg,1,2

Julio S. G. Montaner,1,2 and

P. Richard Harrigan1,2

1British Columbia Centre for Excellence in HIV/AIDS, and 2Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Background.Human leukocyte antigen (HLA) class I variation influences the progression of untreated human immunodeficiency virus (HIV) disease; however, it is not known whether HLA class I variation may influence clinical outcomes after initiation of highly active antiretroviral therapy (HAART).

Methods.Associations between HLA class I genotypes and pretherapy clinical parameters were investigated in a cohort of 765 antiretroviral‐naive adults initiating HAART. Cox proportional hazards regression was used to investigate the effects of HLA class I genotypes on time to suppression of the viral load to <500 HIV RNA copies/mL, time to an increase in the CD4 cell count to >100 cells/mm3 above the baseline count, and time to nonaccidental death over a >5‐year period after initiation of HAART.

Results.Homozygosity at any HLA class I locus and possession of common HLA alleles were associated with a higher pretherapy viral load ( ). In multivariate analyses controlling for sociodemographic and clinical parameters at baseline, HLA class I homozygosity was significantly associated with a poorer CD4 cell response ( ), whereas possession of uncommon HLA alleles was associated with slower virologic suppression after initiation of HAART ( ). We observed no significant association between HLA parameters and time to nonaccidental death after initiation of HAART ( , univariate analysis).

Conclusion.HLA class I zygosity‐dependent and frequency‐dependent effects may influence short‐term HAART outcomes, and, thus, they deserve further investigation. No effects of these HLA parameters on survival after initiation of HAART were observed.

Received 3 October 2006; accepted 18 December 2006; electronically published 24 April 2007.

Reprints or correspondence: Dr. P. Richard Harrigan, BC Centre for Excellence in HIV/AIDS, 603–1081 Burrard St., Vancouver, BC, Canada V6Z 1Y6 ().

Cited by

Toshiaki Nakajima, Akinori Kimura. (2008) Genetic factors that confer sensitivity to HAART in HIV-infected subjects: implication of a benefit of an earlier initiation of HAART. Pharmacogenomics 9:9, 1347-1351
Online publication date: 1-Oct-2008.
CrossRef
Andri Rauch, David Nolan, Hansjakob Furrer, Elizabeth McKinnon, Mina John, Simon Mallal, Silvana Gaudieri, Huldrych F. Günthard, Patrick Schmid, Manuel Battegay, Bernard Hirschel, Amalio Telenti, Ian James, and the Swiss HIV Cohort Study. (2008) HLA‐Bw4 Homozygosity Is Associated with an Impaired CD4 T Cell Recovery after Initiation of Antiretroviral Therapy. Clinical Infectious Diseases 46:12, 1921-1925
Online publication date: 15-Jun-2008.
Abstract-Full Text-PDF Version (284 kB)
Sunil K Ahuja, Hemant Kulkarni, Gabriel Catano, Brian K Agan, Jose F Camargo, Weijing He, Robert J O'Connell, Vincent C Marconi, Judith Delmar, Joseph Eron, Robert A Clark, Simon Frost, Jeffrey Martin, Seema S Ahuja, Steven G Deeks, Susan Little, Douglas Richman, Frederick M Hecht, Matthew J Dolan. (2008) CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1–infected individuals. Nature Medicine 14:4, 413-420
Online publication date: 1-May-2008.
CrossRef
Amalio Telenti, Mary Carrington. (2008) Host factors associated with outcome from primary human immunodeficiency virus-1 infection. Current Opinion in HIV and AIDS 3:1, 28-35
Online publication date: 1-Feb-2008.
CrossRef

  • Potential conflicts of interest: none reported.

    Presented in part: XVIth International AIDS Conference, 13–18 August 2006, Toronto, Canada (abstract MOPE0027).

    Financial support: Michael Smith Foundation for Health Research (doctoral research awards to Z.L.B. and a Senior Scholar Award to R.S.H.); Canadian Institutes for Health Research (postdoctoral and doctoral fellowship award to Z.L.B.).

  • Z.L.B. and C.J.B. contributed equally to this work.

  • Present affiliation: Partners AIDS Research Center, Massachusetts General Hospital, Boston.

Back to Top
Close Popup